Human Biotech Animal Health Partnering | Kisaco Research
Innovating veterinary health with human biotechnology
Boston, USA
12-13 March, 2018
Download Agenda
The Audience
Register

Why Attend

Join the first ever conference connecting human biotechs with the animal health industry.

Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.

Benefits of the Animal Health industry to Biotechs:

1st
conference of its kind
100+
Attendees
20+
1-to-1 Meetings per person

Who Will Be There

40%
Human Biotechs
40%
Animal Health Companies
20%
Investors and Service Providers

WHO SHOULD ATTEND?

HUMAN BIOTECHNOLOGY

Chief Executive Officers, Chief Scientific Officers, Chief Business Officers and corporate leadership from human biotechs working on technologies in fields including but not limited to:

 

ANIMAL HEALTH

-  Directors of External Innovation & Business Development from leading Animal Health Pharmaceutical and Nutrition Companies
-  Market Intelligence and Consultancy Providers

 

INVESTMENT & SERVICE PROVIDERS

-  Private Equity & Venture Capital Investors
-  Investment Bankers & M&A advisors
-  Legal Advisory

Benefits of Attending

 

  1. Explore opportunities for generating non-dilutive income, validating and de-risking human research, and maximizing IP assets in our myth-busting case studies of human biotech and animal health partnerships.
  2. Forge relationships with animal health executives in pre-scheduled 1-on-1 meetings, and discuss research collaborations, deal-licensing and other business development opportunities.
  3. Discuss unmet medical needs in veterinary health, and learn how the regulatory road works, how the industry operates and which technologies are of interest to animal pharmaceutical and nutrition companies.
  4. Identify commercial potential in your translational technologies with investors and advisory firms specializing in the veterinary health industry.

The Speakers

 

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Scott Brown

VP, Head of External Innovation
Zoetis

Scott Brown

VP, Head of External Innovation
Zoetis
 

Christine Adreani

Director, Translation In Vivo Models Global Research Platform
Sanofi Genzyme

Christine Adreani

Director, Translation In Vivo Models Global Research Platform
Sanofi Genzyme
 

Atsushi Nagahisa

Founder & Innovation Advisor
RaQualia Pharma Inc.

Atsushi Nagahisa, Ph.D., is President of DNA Partners LLC.  Prior to forming DNA Partners, Dr. Nagahisa served on the Board of Directors of RaQualia Pharma Inc. (RaQualia), a biopharmaceutical venture he founded in 2008.  He served as Representative Director, President and CEO of RaQualia from its inception through August 2012.  Dr.

Atsushi Nagahisa

Founder & Innovation Advisor
RaQualia Pharma Inc.

Atsushi Nagahisa, Ph.D., is President of DNA Partners LLC.  Prior to forming DNA Partners, Dr. Nagahisa served on the Board of Directors of RaQualia Pharma Inc. (RaQualia), a biopharmaceutical venture he founded in 2008.  He served as Representative Director, President and CEO of RaQualia from its inception through August 2012.  Dr.

 

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago.

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago.

 

Linda Rhodes

VMD, PhD

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

 

Steven St. Peter

CEO
Aratana Therapeutics

Steven St. Peter, M.D. is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries.

Steven St. Peter

CEO
Aratana Therapeutics

Steven St. Peter, M.D. is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries.

 

Stephen Martin

Head of Global Pharmaceutical R&D
Boehringer Ingelheim Animal Health

As Head of Global Pharmaceutical R&D at Boehringer Ingelheim Animal Health Stephen Martin has:

Stephen Martin

Head of Global Pharmaceutical R&D
Boehringer Ingelheim Animal Health

As Head of Global Pharmaceutical R&D at Boehringer Ingelheim Animal Health Stephen Martin has:

 

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis.

Dorothy Brown

Senior Research Advisor, Translational Comparative Medical Research (TCMR)
Elanco

Dottie is the lead executional scientist for TCMR at Eli Lilly/Elanco. TCMR facilitates companion animal studies designed to de-risk assets in the Lilly pipeline, as well as assets of potential Lilly partners. At the University of Pennsylvania, Dottie led a sponsored translational research program focusing on the development of outcome assessment instruments for chronic pain in companion animals and applying those instruments to translational studies evaluating the efficacy of novel interventions, such as targeted neurotoxins, in dogs with naturally occurring bone cancer or osteoarthritis.

 

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry.

Peter Hanson

Chief Veterinary Officer and EVP Clinical Operations & CMC
Centrexion Therapeutics

Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals.  Peter started his career as a practicing veterinarian and has spent the last 21 years in industry.

 

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis.

Ailis Tweed-Kent

CEO
Cocoon Biotech

Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first-hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics for osteoarthritis.

 

Brian Kopp

Partner
Stonehaven Consulting

Brian Kopp is a Partner at Stonehaven Consulting AG.  He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors.  Since 2007, Brian has served as CFO and V.P.

Brian Kopp

Partner
Stonehaven Consulting

Brian Kopp is a Partner at Stonehaven Consulting AG.  He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors.  Since 2007, Brian has served as CFO and V.P.

 

Sean Ekins

CEO
Collaborations Pharma

Sean Ekins

CEO
Collaborations Pharma
 

Heather Wasserman

Senior Director
Eli Lilly and Company

Heather Wasserman

Senior Director
Eli Lilly and Company

Headline Partner

Associate Partners

Event Partner

The Agenda

 

Download Full Agenda

Conference Packages

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: discounts cannot be combined.

Sunday, November 12, 2017 to Saturday, March 31, 2018
Start-Up Pass
$699
Standard rate
Companies pre-Series B funding
Email Jessica if you’d like to bring your investors for a reduced fee of $199: [email protected]
Sunday, November 12, 2017 to Thursday, December 21, 2017
Delegate Pass
$1,599
Early Bird available until Wednesday, December 20th
Human Biotechs
Animal Health Companies
Consultants
Service Providers
Sunday, November 12, 2017 to Saturday, March 31, 2018
Investor Pass
$699
Standard rate
Preparing registration...

Book a Team to Save More!

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Animal Health Investment Europe:

  • Please note that a $70 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • PLEASE NOTE – no additional discounts are available on ‘Start-up Company’ pricing. Group discounts are ONLY available on ‘Delegate’ pricing.

Become a Sponsor or Exhibitor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Resources

Download Resource